LAMIVUDINE and PYREXIA

Overview

PYREXIA is the #8 most commonly reported adverse reaction for LAMIVUDINE, manufactured by ViiV Healthcare Company. There are 1,265 FDA adverse event reports linking LAMIVUDINE to PYREXIA. This represents approximately 2.2% of all 57,073 adverse event reports for this drug.

Patients taking LAMIVUDINE who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PYREXIA is a less commonly reported adverse event for LAMIVUDINE, but still significant enough to appear in the safety profile.

Other Side Effects of LAMIVUDINE

In addition to pyrexia, the following adverse reactions have been reported for LAMIVUDINE:

• FOETAL EXPOSURE DURING PREGNANCY — 2,012 reports
• VIROLOGIC FAILURE — 1,948 reports
• DRUG RESISTANCE — 1,941 reports
• DRUG INTERACTION — 1,850 reports
• PATHOGEN RESISTANCE — 1,724 reports
• VIRAL MUTATION IDENTIFIED — 1,665 reports
• DEPRESSION — 1,330 reports
• DRUG INEFFECTIVE — 1,132 reports
• ANAEMIA — 1,117 reports
• PAIN — 1,105 reports

Other Drugs Associated with PYREXIA

The following drugs have also been linked to pyrexia in FDA adverse event reports:

Does LAMIVUDINE cause PYREXIA?

PYREXIA has been reported as an adverse event in 1,265 FDA reports for LAMIVUDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PYREXIA with LAMIVUDINE?

PYREXIA accounts for approximately 2.2% of all adverse event reports for LAMIVUDINE, making it a notable side effect.

What should I do if I experience PYREXIA while taking LAMIVUDINE?

If you experience pyrexia while taking LAMIVUDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages